BMR.H Bradmer Pharmaceuticals

Bradmer Pharmaceuticals Inc. (TSX VENTURE:BMR.H) ("Bradmer") announced today
that its license agreement with Duke University has been terminated. Pursuant to
the license agreement, Bradmer licensed certain patent rights relating to a
drug, termed Neuradiab(R), for the treatment of glioblastoma multiforme, the
most common and advanced form of primary brain cancer. Bradmer's Phase III
clinical trial for Neuradiab was suspended in March 2009 and Bradmer has not
pursued any activities relating to the clinical development of Neuradiab since
that date.


Bradmer is continuing to negotiate with P1 Energy Corp. ("P1 Energy") the terms
of a definitive agreement in respect of their previously announced business
combination (the "Transaction"). Completion of the Transaction remains subject
to a number of conditions. For further information concerning P1 Energy and the
proposed Transaction, please see Bradmer's news release dated February 9, 2011.


Additional information about Bradmer, including the MD&A and financial results
may be found on SEDAR at www.sedar.com.


Bradmer's common shares have not been registered under the Securities Act of
1933, as amended (the "Securities Act") or any state regulatory agency in the
United States. The resale or transfer by a U.S. investor of such common shares
of Bradmer Pharmaceuticals Inc. is subject to the requirements of Rule 904 of
Regulation S of the Securities Act or such other applicable exemption
thereunder, and other applicable state securities laws.

Grafico Azioni Bradmer Pharmaceuticals (TSXV:BMR.H)
Storico
Da Mag 2024 a Giu 2024

Grafico Azioni Bradmer Pharmaceuticals (TSXV:BMR.H)
Storico
Da Giu 2023 a Giu 2024